IRadimed (IRMD) Osake Kurssi
IRadimed Kurssi
Liikevaihto on kasvanut 20,2 % vuodessa viimeisten 13 vuoden aikana 83,81 M USD:een. Osakekohtainen tulos on kasvanut 22,8 % vuodessa viimeisten 13 vuoden aikana. IRadimedn nettomarginaali on nyt 26,8 %, noussut 22,3 %:sta muutama vuosi sitten. IRadimedn osinkotuotto on tällä hetkellä noin 1,36 %. Jakosuhde on noin 68 % tuloksesta. Osinko on kasvanut 5,7 % vuodessa viimeisten 3 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 120,00 USD, eli yli nykyhintaa 38,3 %. 8 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
IRadimed osakekurssi
IRadimed liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset IRadimed -osakkeesta
IRadimed Corp, a leading provider of innovative magnetic resonance imaging (MRI) solutions, operates under a unique business model. The company specializes in the design, development, and manufacturing of groundbreaking MRI-compatible intravenous (IV) infusion pumps and related products. By focusing on this niche market, IRadimed Corp has established a strong competitive advantage. Their technologically advanced and FDA-approved products enable safe and precise delivery of fluids to patients during MRI procedures. Through strategic partnerships and a commitment to delivering high-quality healthcare solutions, IRadimed Corp continues to expand its presence in the global MRI market, enhancing patient care and revolutionizing the way IV infusion is administered in MRI settings.
IRadimed Corp is primarily active in the healthcare industry, specifically specializing in the development and manufacturing of innovative medical devices. The company focuses on creating advanced solutions for the delivery of intravenous medications and infusion therapy. With a strong presence in the medical technology sector, IRadimed Corp aims to improve patient care and enhance clinical outcomes through their cutting-edge products.
The main competitors of IRadimed Corp in the market are [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same industry as IRadimed Corp and offer similar products and services. However, IRadimed Corp stands out with its unique features, strong customer base, and innovative solutions. Despite facing competition, IRadimed Corp has managed to maintain a strong position in the market through its superior offerings and customer satisfaction.
IRadimed Corp, founded in 1992, is a leading provider of innovative magnetic resonance imaging (MRI) solutions. Headquartered in Winter Springs, Florida, the company specializes in the development and manufacturing of innovative MRI-compatible medical devices, including infusion pumps and vital signs monitoring systems. With a focus on patient safety and advanced technology, IRadimed Corp has established itself as a trusted name in the healthcare industry. The company's dedication to research and development has resulted in numerous patents and partnerships with top medical institutions. IRadimed Corp continues to expand its product portfolio and enhance healthcare outcomes through its cutting-edge solutions.
IRadimed Corp has achieved several significant milestones since its inception. The company has successfully introduced innovative medical device solutions, focusing on the development of MRI-compatible patient monitoring systems. With its cutting-edge technology, IRadimed Corp has revolutionized the healthcare industry by providing safe and accurate monitoring options for patients undergoing Magnetic Resonance Imaging (MRI) scans. The company's milestones include receiving FDA clearance for various products, expanding its global presence, securing strategic partnerships, and consistently offering high-quality, reliable products that enhance patient care during MRI procedures. IRadimed Corp's commitment to innovation and excellence has solidified its position as a leader in the MRI-compatible patient monitoring market.
IRadimed Corp is primarily present in the United States.
IRadimed Corp represents a commitment to innovation, excellence, and patient care. As a leading medical device company, their corporate philosophy centers around developing cutting-edge imaging solutions that enhance patient outcomes. IRadimed Corp values integrity, collaboration, and continuous improvement. Through their dedication to research and development, they strive to provide healthcare professionals with state-of-the-art products that improve diagnostic accuracy and patient safety. With a focus on customer satisfaction and clinical effectiveness, IRadimed Corp is dedicated to advancing the field of medical imaging and positively impacting the lives of patients worldwide.
Analyytikot asettavat tällä hetkellä IRadimed-osakkeelle keskimääräisen tavoitehinnan 100,00 USD (mediaani: 120,00 USD), mikä merkitsee +15,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
8 analyytikkoa arvioi tällä hetkellä IRadimed-osaketta: 7 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat IRadimed-yhtiöltä 92,07 M USD liikevaihtoa ja 2,11 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla IRadimed-osake noteerataan hintaan 77,45 EUR (86,79 USD).
IRadimed-osake (IRMD) on listattuna 3 pörssissä, muun muassa: NASDAQ (IRMD), Frankfurt (46K.F), Hamburg (46K.HM).
IRadimed Corp is a leading company and manufacturer of innovative medical devices and systems for use in healthcare. The company is known for its high-quality products and patented design, which allows for fast, secure, and efficient transmission of medical data. IRadimed Corp is divided into various business segments, which include a variety of products such as magnetic resonance imaging (MRI), intravenous contrast media injection, and invasive pressure monitoring. The MRI product line of IRadimed Corp is unique in the market and includes the MRidium system, specifically designed for use in magnetic resonance imaging rooms (MRI). The system is designed to meet the requirements of patient and image safety in the MRI room and allows for optimal and accurate patient monitoring. Other significant products of IRadimed Corp include the Flow-i anesthesia device and the InPatient satellite monitoring system. The Flow-i anesthesia device is a revolutionary development in anesthesiology and provides precise dosing of anesthetics and a quick response to patient needs. The InPatient satellite monitoring system allows medical personnel to monitor patients with real-time data from a central monitoring area. IRadimed Corp has a strong focus on research and development and continuously works to develop new products and technologies to meet the needs of healthcare. The company has a strong presence in the global market and is known for its high-quality products and excellent technical support and customer service. IRadimed Corp also has strong partnerships with companies like Siemens and Philips in the field of MRI technology and continuously works to improve both the technological capabilities and applicability of its products. Additionally, the company is actively involved in the community and participates in charity events and donation drives to make a positive contribution to society. Overall, IRadimed Corp is an innovative and advanced company focused on developing and providing cutting-edge products in healthcare. With a strong focus on technology and design and a commitment to excellent customer service, IRadimed Corp has achieved a leading position in the market and continues its successful corporate development.
odotettu liikevaihto IRadimed on 92,07 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto IRadimed on 27,16 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
IRadimed:n hinta-voitto-suhde (P/E) on tällä hetkellä 41,13. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IRadimed-osakkeen arvostusta.
IRadimed:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,14. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IRadimed-osakkeen arvostuskennuslukuna.
IRadimed:n Eulpool-laatuscore on 7/10.
IRadimed:n ISIN on US46266A1097. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
IRadimed:n WKN on A118V4. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
IRadimed:n ticker on IRMD. Tämä pörssinoteeraus käytetään IRadimed-osakkeiden kauppaan pörssissä.
IRadimed osake
IRadimed vertaisryhmä
IRadimed Ticker
IRadimed FIGI
Kaikki tunnusluvut ja syvällinen analyysi IRadimed:sta
Meidän osakeanalyysimme IRadimed-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut IRadimed:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: